Abstract
Targeting type I interferon immune responses is a potential strategy for the treatment of systemic lupus erythematosus. Although a phase 2 clinical trial of anifrolumab did not meet its primary end point, further studies are needed to assess the effects of interferon blockade on flare rates of lupus nephritis. However, the observed higher risk of herpes zoster associated with anifrolumab use suggests that caution is warranted with this strategy.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Fakultät: | Medizin |
Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
ISSN: | 1759-5061 |
Sprache: | Englisch |
Dokumenten ID: | 112641 |
Datum der Veröffentlichung auf Open Access LMU: | 02. Apr. 2024, 07:38 |
Letzte Änderungen: | 02. Apr. 2024, 07:38 |